For the quarter ending 2026-03-31, PVCT had -$27,408 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -1,300,949 | -1,167,812 | -1,323,629 | -3,013,683 |
| Stock-based compensation | 306,051 | 287,601 | 312,775 | 637,170 |
| Non-cash operating lease expense | 11,967 | 11,823 | 11,682 | 24,623 |
| Short term receivables | - | - | - | 0 |
| Depreciation | 466 | 465 | 466 | 932 |
| Unearned grant revenue | - | 0 | 0 | -336,108 |
| Prepaid expenses and other current assets | -80,081 | -87,609 | -55,580 | -335,198 |
| Accounts payable | 99,095 | -461,556 | -133,263 | 204,488 |
| Accrued interest | 50,422 | 46,708 | 46,936 | 108,128 |
| Other accrued expenses | 406,932 | 337,094 | 200,929 | 447,980 |
| Operating lease liability | -11,630 | -11,485 | -11,343 | -25,299 |
| Net cash used in operating activities | -357,565 | -869,553 | -839,867 | -1,616,571 |
| Repayment of 2021 convertible note payable - related party | - | - | - | 0 |
| Repayment of short-term note payable | - | - | - | -152,126 |
| Proceeds from issuance of convertible notes payable | 110,000 | 320,000 | 550,000 | 0 |
| Proceeds from issuance of convertible notes payable - related parties | 225,000 | 665,000 | -20,000 | 995,000 |
| Proceeds from issuance of common stock of majority-owned subsidiary | 75,000 | 150,000 | 0 | 700,000 |
| Repayment of short-term notes payable | 80,128 | 86,771 | 186,223 | - |
| Net cash provided by financing activities | 329,872 | 1,048,229 | 495,903 | 1,542,874 |
| Effect of exchange rates on cash and restricted cash | 285 | 136 | -28 | 442 |
| Net decrease in cash and restricted cash | -27,408 | 178,812 | -343,992 | -73,255 |
| Cash and restricted cash, beginning of period | 251,291 | 72,479 | 489,726 | - |
| Cash and restricted cash, end of period | 223,883 | 251,291 | 72,479 | - |
| Cash | - | 251,291 | - | - |
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)